Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Advent identifies five trends for alternatives in 2013

Friday, January 11, 2013

Beverly Chandler, Opalesque London: Advent Software has identified what it believes to be five key trends for alternatives over 2013. It writes that in 2012, the global alternative investment industry continued to grapple with the Eurozone debt crisis, a slowing of growth in Asia and the sluggishness of the US recovery. "European funds saw mixed results in a volatile market trying to come to grips with uncertainty in Greece and Spain. In Asia, hedge funds saw a return to positive performance following the previous year’s negative numbers, yet many funds in the region shut down and more may follow. US funds, too, bounced back from a down year, although overall performance has thus far lagged the S&P 500. Hedge fund capital invested in emerging markets reached record levels".

Further challenges to funds have come as they have had to assimilate and adjust to the regulatory tentacles of Dodd-Frank in the US and Europe’s AIFM Directive and EMIR. "Five years later, the effects of 2008 still reverberate" Advent says.

Based on conversations with alternative investment clients, including hedge funds, administrators and prime brokers, as well as internal consultants, the firm has identified the top five trends affecting the alternative industry in 2013. "While not scientific, these predictions are based on what we’ve heard from our investment management clients as well as the opinions of our own subject matter experts" they say.......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for